CGON250117P40000
- 9.50
- 0.000.00%
CG Oncology Newsroom
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Cuts Target Price to $83
LifeSci Capital Remains a Buy on CG Oncology, Inc. (CGON)
CG Oncology Shares Are Trading Higher After TD Cowen Initiated Coverage on the Stock With a Buy Rating.
CG Oncology Analyst Ratings
TD Cowen Initiates CG Oncology(CGON.US) With Buy Rating
How to Navigate the Stock and Bond Markets in 2025 -- Journal Report
This Insider Has Just Sold Shares In CG Oncology
CG Oncology Insider Sold Shares Worth $19,600,000, According to a Recent SEC Filing
CG Oncology(CGON.US) Director Sells US$19.6 Million in Common Stock
Press Release: CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
CG Oncology: Morgan Stanley, Goldman Sachs AMong Managers for Offering >CGON
CG Oncology Oncology Has Granted Underwriters Option for Additional 1,200,000 Shares >CGON
CG Oncology Offering Price Set at $28.00 Per Share >CGON
Why CG Oncology (CGON) Stock Is Down 9%
CG Oncology Announces Proposed Public Offering of 7.3M Shares
CG Oncology Announces Proposed Public Offering
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Insider Sale: Director at $CGON (CGON) Sells 750 Shares
Express News | RBC Capital Reiterates Outperform on CG Oncology, Maintains $66 Price Target